These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 37508471)

  • 1. Exploring Rosiglitazone's Potential to Treat Alzheimer's Disease through the Modulation of Brain-Derived Neurotrophic Factor.
    Nelson ML; Pfeifer JA; Hickey JP; Collins AE; Kalisch BE
    Biology (Basel); 2023 Jul; 12(7):. PubMed ID: 37508471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the Neuroprotective Potential of Rosiglitazone Embedded Nanocarrier System on Streptozotocin Induced Mice Model of Alzheimer's Disease.
    K C S; Kakoty V; Marathe S; Chitkara D; Taliyan R
    Neurotox Res; 2021 Apr; 39(2):240-255. PubMed ID: 32683650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Tale of Two Diseases: Exploring Mechanisms Linking Diabetes Mellitus with Alzheimer's Disease.
    Lynn J; Park M; Ogunwale C; Acquaah-Mensah GK
    J Alzheimers Dis; 2022; 85(2):485-501. PubMed ID: 34842187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
    Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
    J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exenatide Reverts the High-Fat-Diet-Induced Impairment of BDNF Signaling and Inflammatory Response in an Animal Model of Alzheimer's Disease.
    Bomba M; Granzotto A; Castelli V; Onofrj M; Lattanzio R; Cimini A; Sensi SL
    J Alzheimers Dis; 2019; 70(3):793-810. PubMed ID: 31256135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z; Zhong C
    Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease.
    Cummings J; Ortiz A; Castellino J; Kinney J
    Eur J Neurosci; 2022 Nov; 56(9):5727-5757. PubMed ID: 35128745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of glucagon-like peptide-1 analogue; Exendin-4, on cognitive functions in type 2 diabetes mellitus; possible modulation of brain derived neurotrophic factor and brain Visfatin.
    Abdelwahed OM; Tork OM; Gamal El Din MM; Rashed L; Zickri M
    Brain Res Bull; 2018 May; 139():67-80. PubMed ID: 29421245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer's disease.
    Hsu WJ; Wildburger NC; Haidacher SJ; Nenov MN; Folorunso O; Singh AK; Chesson BC; Franklin WF; Cortez I; Sadygov RG; Dineley KT; Rudra JS; Taglialatela G; Lichti CF; Denner L; Laezza F
    Exp Neurol; 2017 Sep; 295():1-17. PubMed ID: 28522250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive enhancement with rosiglitazone links the hippocampal PPARγ and ERK MAPK signaling pathways.
    Denner LA; Rodriguez-Rivera J; Haidacher SJ; Jahrling JB; Carmical JR; Hernandez CM; Zhao Y; Sadygov RG; Starkey JM; Spratt H; Luxon BA; Wood TG; Dineley KT
    J Neurosci; 2012 Nov; 32(47):16725-35a. PubMed ID: 23175826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.
    Hölscher C
    Biochem Soc Trans; 2011 Aug; 39(4):891-7. PubMed ID: 21787319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease.
    Haan MN
    Nat Clin Pract Neurol; 2006 Mar; 2(3):159-66. PubMed ID: 16932542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer's Disease.
    Adem MA; Decourt B; Sabbagh MN
    Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38255204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of peroxisome proliferator-activated receptor α/γ agonists may benefit type 2 diabetes patients with coronary artery disease through inhibition of inflammatory cytokine secretion.
    Wei J; Tang Q; Liu L; Bin J
    Exp Ther Med; 2013 Mar; 5(3):783-788. PubMed ID: 23408783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease.
    Peng S; Wuu J; Mufson EJ; Fahnestock M
    J Neurochem; 2005 Jun; 93(6):1412-21. PubMed ID: 15935057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study.
    Watson GS; Cholerton BA; Reger MA; Baker LD; Plymate SR; Asthana S; Fishel MA; Kulstad JJ; Green PS; Cook DG; Kahn SE; Keeling ML; Craft S
    Am J Geriatr Psychiatry; 2005 Nov; 13(11):950-8. PubMed ID: 16286438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut-brain axis through the lens of gut microbiota and their relationships with Alzheimer's disease pathology: Review and recommendations.
    L K; Ng TKS; Wee HN; Ching J
    Mech Ageing Dev; 2023 Apr; 211():111787. PubMed ID: 36736919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comorbidity Analysis between Alzheimer's Disease and Type 2 Diabetes Mellitus (T2DM) Based on Shared Pathways and the Role of T2DM Drugs.
    Karki R; Kodamullil AT; Hofmann-Apitius M
    J Alzheimers Dis; 2017; 60(2):721-731. PubMed ID: 28922161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.
    Gold M; Alderton C; Zvartau-Hind M; Egginton S; Saunders AM; Irizarry M; Craft S; Landreth G; Linnamägi U; Sawchak S
    Dement Geriatr Cogn Disord; 2010; 30(2):131-46. PubMed ID: 20733306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications.
    Jiang Q; Heneka M; Landreth GE
    CNS Drugs; 2008; 22(1):1-14. PubMed ID: 18072811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.